SAENTA-I | 1191264-94-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: SAENTA-I
• 英文别名: N-(6-(2-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(4-nitrobenzylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methylthio)ethylamino)-6-oxohexyl)-3-iodobenzamide；N-[6-[2-[[(2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(4-nitrophenyl)methylamino]purin-9-yl]oxolan-2-yl]methylsulfanyl]ethylamino]-6-oxohexyl]-3-iodobenzamide
• CAS: 1191264-94-4
• 化学式: C₃₂H₃₇IN₈O₇S
• 分子量: 804.666
• InChiKey: CJQJDNQJPCHEES-SLXDEKLDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  49
• 可旋转键数：
  16
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  235
• 氢给体数：
  5
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  TFA*H2N-SAENTA 、 N-琥珀酰亚胺 3-碘苯甲酸酯 在 2,4,6-三甲基吡啶 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 48.0h， 以28%的产率得到SAENTA-I
  参考文献：
  名称：

  Towards to hENT1-nucleoside transporter selective imaging agents. Synthesis and in vitro evaluation of the radiolabeled SAENTA analogues

  摘要：

  Three new potential hENT(1) inhibitors suitable for labeling with PET/SPECT radioisotopes were prepared from an advanced intermediate 4. They were tested for their capability to inhibit binding of SAENTA-fluorescein to HL60 leukemia cells in flow cytometry assay and SAENTA-I (5) was determined to be the most active compound. I-131-5 showed high hENT(1)-specific binding (up to 54% ID) to 6 from 7 tested tumor cell lines and was chosen for further in vivo study. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.017

文献信息

• Towards to hENT1-nucleoside transporter selective imaging agents. Synthesis and in vitro evaluation of the radiolabeled SAENTA analogues
  作者：Boris D. Zlatopolskiy、Agnieszka Morgenroth、Elizaveta A. Urusova、Cornelia Dinger、Thomas Kull、Manuela Pape、Gerhard Glatting、Sven N. Reske

  DOI：10.1016/j.bmcl.2009.07.017

  日期：2009.9

  Three new potential hENT(1) inhibitors suitable for labeling with PET/SPECT radioisotopes were prepared from an advanced intermediate 4. They were tested for their capability to inhibit binding of SAENTA-fluorescein to HL60 leukemia cells in flow cytometry assay and SAENTA-I (5) was determined to be the most active compound. I-131-5 showed high hENT(1)-specific binding (up to 54% ID) to 6 from 7 tested tumor cell lines and was chosen for further in vivo study. (C) 2009 Elsevier Ltd. All rights reserved.